Utilisation of macrolides and the development of Streptococcus pyogenes resistance to erythromycin
Jazyk angličtina Země Německo Médium print
Typ dokumentu srovnávací studie, časopisecké články, práce podpořená grantem
- MeSH
- antibakteriální látky farmakologie terapeutické užití MeSH
- bakteriální léková rezistence * MeSH
- časové faktory MeSH
- erythromycin farmakologie terapeutické užití MeSH
- hodnocení spotřeby léčiv statistika a číselné údaje trendy MeSH
- lidé MeSH
- mikrobiální testy citlivosti metody MeSH
- Streptococcus pyogenes účinky léků izolace a purifikace MeSH
- streptokokové infekce farmakoterapie mikrobiologie MeSH
- tonzilitida farmakoterapie mikrobiologie MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- srovnávací studie MeSH
- Geografické názvy
- Česká republika MeSH
- Názvy látek
- antibakteriální látky MeSH
- erythromycin MeSH
OBJECTIVES: The aim of the study was to evaluate the relationship between the development of the resistance of Streptococcus pyogenes strains to erythromycin and the utilisation of macrolides in the Olomouc region, Czech Republic. METHOD: During the period 1997-2001, data for utilisation of macrolides was obtained from the database of the regional General Health Insurance Company and expressed indefined daily doses per 1,000 patients per day. S. pyogenes strains were isolated from community patients suffering from acute bacterial tonsillitis. Their susceptibility to antibiotics was assessed by the disk diffusion method. RESULTS: Utilisation of macrolides increased by 13% in the period 1997-2001; their utilisation represented 11.40% of total antibiotic prescription in 1997 and 15.48% in 2001. Occurrence of erythromycin-resistant S. pyogenes strains increased significantly from 14% in 1997 to 32% in the year 2001 (P < 0.01). In 2000, macrolides consumption decreased non-significantly, but with no concomitant decrease in erythromycin-resistant S. pyogenes strains occurrence. Absolute susceptibility of S. pyogenes, the most important bacterial pathogen in community-acquired bacterial tonsillitis, to penicillin contrasts with increasing macrolide resistance. CONCLUSIONS: The study documents the influence of increased utilisation of macrolides on bacterial resistance. Penicillin should be a first-choice antibiotic in acute bacterial tornsillitis; macrolides should only be reserved for patients allergic to penicillins.
Zobrazit více v PubMed
Lancet. 2001 Jun 9;357(9271):1851-3 PubMed
Antimicrob Agents Chemother. 1999 Jan;43(1):48-52 PubMed
Pediatr Clin North Am. 1995 Jun;42(3):539-51 PubMed
N Engl J Med. 1992 Jan 30;326(5):292-7 PubMed
Eur J Clin Microbiol Infect Dis. 1998 Jan;17(1):25-31 PubMed
Antimicrob Agents Chemother. 1999 Aug;43(8):1935-40 PubMed
Scand J Infect Dis. 1990;22(2):179-85 PubMed
J Antimicrob Chemother. 2000 Dec;46(6):959-64 PubMed
J Antimicrob Chemother. 1993 Dec;32(6):885-91 PubMed
N Engl J Med. 1997 Aug 14;337(7):441-6 PubMed
Antimicrob Agents Chemother. 1996 Aug;40(8):1817-24 PubMed
Emerg Infect Dis. 1996 Oct-Dec;2(4):339-42 PubMed
Clin Infect Dis. 1995 Dec;21(6):1378-85 PubMed
Antimicrob Agents Chemother. 2001 Dec;45(12):3334-40 PubMed
J Clin Microbiol. 1999 Jun;37(6):1727-31 PubMed
Antimicrob Agents Chemother. 1973 Sep;4(3):327-31 PubMed
J Antimicrob Chemother. 1990 Apr;25(4):723-4 PubMed
Implementation of Antibiotic Stewardship in a University Hospital Setting
